George Stergiou1, Emelina Stambolliu2, Ioanna Bountzona2, Angeliki Ntineri2, Anastasios Kollias2, Andriani Vazeou3, Alexandra Soldatou4. 1. Hypertension Center STRIDE-7, National and Kapodistrian University of Athens, School of Medicine, Third Department of Medicine, Sotiria Hospital, Athens, Greece. stergiougs@gmail.com. 2. Hypertension Center STRIDE-7, National and Kapodistrian University of Athens, School of Medicine, Third Department of Medicine, Sotiria Hospital, Athens, Greece. 3. First Department of Pediatrics, P&A Kyriakou Children's Hospital, Athens, Greece. 4. Second Department of Pediatrics, National and Kapodistrian University of Athens, School of Medicine, P&A Kyriakou Children's Hospital, Athens, Greece.
Abstract
PURPOSE OF REVIEW: For the accurate diagnosis and management of hypertension, out-of-office blood pressure evaluation using ambulatory (ABPM) or home monitoring (HBPM) is currently recommended. In children, there is considerable evidence on the clinical utility of ABPM, whereas the evidence on HBPM is limited. This systematic review presents (i) the benefits of HBPM in children; (ii) the evidence on normal range, diagnostic accuracy, and relationship with preclinical organ damage; and (iii) guidance for devices, monitoring schedule, and interpretation. RECENT FINDINGS: HBPM is a useful adjunct to the conventional office measurements for the evaluation of children with suspected or treated hypertension. HBPM is feasible in children and has good reproducibility, diagnostic accuracy and acceptability by users, and relatively low cost. Thus, it has greater potential for widespread and long-term use than ABPM, which is more expensive and often not available or not tolerated. Automated monitors that have been clinically validated specifically in children should be used with appropriate cuff size. HBPM for 7 days (minimum 3) with duplicate morning and evening measurements (minimum 12 readings) should be performed in children with suspected or treated hypertension before each office visit. Until more data become available, in case of diagnostic disagreement between office blood pressure and HBPM, treatment decisions should be based on ABPM. HBPM is clinically useful in children with hypertension. More research is needed on its clinical application, and more automated devices need to be clinically validated in this population.
PURPOSE OF REVIEW: For the accurate diagnosis and management of hypertension, out-of-office blood pressure evaluation using ambulatory (ABPM) or home monitoring (HBPM) is currently recommended. In children, there is considerable evidence on the clinical utility of ABPM, whereas the evidence on HBPM is limited. This systematic review presents (i) the benefits of HBPM in children; (ii) the evidence on normal range, diagnostic accuracy, and relationship with preclinical organ damage; and (iii) guidance for devices, monitoring schedule, and interpretation. RECENT FINDINGS: HBPM is a useful adjunct to the conventional office measurements for the evaluation of children with suspected or treated hypertension. HBPM is feasible in children and has good reproducibility, diagnostic accuracy and acceptability by users, and relatively low cost. Thus, it has greater potential for widespread and long-term use than ABPM, which is more expensive and often not available or not tolerated. Automated monitors that have been clinically validated specifically in children should be used with appropriate cuff size. HBPM for 7 days (minimum 3) with duplicate morning and evening measurements (minimum 12 readings) should be performed in children with suspected or treated hypertension before each office visit. Until more data become available, in case of diagnostic disagreement between office blood pressure and HBPM, treatment decisions should be based on ABPM. HBPM is clinically useful in children with hypertension. More research is needed on its clinical application, and more automated devices need to be clinically validated in this population.
Entities:
Keywords:
Ambulatory blood pressure monitoring; Diagnosis; Masked hypertension; Out of office; Self-measurement; White coat hypertension
Authors: Erwin Kitzmueller; Andreas Vécsei; Judith Pichler; Michael Böhm; Thomas Müller; Regina Vargha; Dagmar Csaicsich; Christoph Aufricht Journal: Pediatr Nephrol Date: 2004-12 Impact factor: 3.714
Authors: George S Stergiou; Christina V Alamara; Eleanna V Salgami; Iraklis N Vaindirlis; Catherine Dacou-Voutetakis; Theodore D Mountokalakis Journal: Blood Press Monit Date: 2005-06 Impact factor: 1.444
Authors: George S Stergiou; Nikolaos M Baibas; Alexandra P Gantzarou; Irini I Skeva; Chrysa B Kalkana; Leonidas G Roussias; Theodore D Mountokalakis Journal: Am J Hypertens Date: 2002-02 Impact factor: 2.689
Authors: George S Stergiou; Christina V Alamara; Chrysa B Kalkana; Iraklis N Vaindirlis; Constantinos J Stefanidis; Catherine Dacou-Voutetakis; Theodore D Mountokalakis Journal: Am J Hypertens Date: 2004-10 Impact factor: 2.689
Authors: Empar Lurbe; Josep Redon; Ajit Kesani; Jose Maria Pascual; Jose Tacons; Vicente Alvarez; Daniel Batlle Journal: N Engl J Med Date: 2002-09-12 Impact factor: 91.245
Authors: Béatrice Bouhanick; Philippe Sosner; Karine Brochard; Claire Mounier-Véhier; Geneviève Plu-Bureau; Sébastien Hascoet; Bruno Ranchin; Christine Pietrement; Laetitia Martinerie; Jean Marc Boivin; Jean Pierre Fauvel; Justine Bacchetta Journal: Front Pediatr Date: 2021-07-07 Impact factor: 3.418
Authors: Fabiana G A M Feitosa; Audes D M Feitosa; Marco A Mota-Gomes; Annelise M G Paiva; Weimar S Barroso; Roberto D Miranda; Eduardo C D Barbosa; Andréa A Brandão; Thiago S V Jardim; Paulo C B V Jardim; Arthur B M Feitosa; Maria V C Santos; José L Lima-Filho; Andrei C Sposito; Wilson Nadruz Journal: J Clin Hypertens (Greenwich) Date: 2021-12-09 Impact factor: 3.738